MicroRNAs, Long Non-Coding RNAs, and Circular RNAs: Potential Biomarkers and Therapeutic Targets in Pheochromocytoma/Paraganglioma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33810219

Citations 12

Authors

Peter Istvan Turai

Gabor Nyiro

Henriett Butz

Attila Patocs

Peter Igaz

Affiliations

Soon will be listed here.

Abstract

Around 40% of pheochromocytomas/paragangliomas (PPGL) harbor germline mutations, representing the highest heritability among human tumors. All PPGL have metastatic potential, but metastatic PPGL is overall rare. There is no available molecular marker for the metastatic potential of these tumors, and the diagnosis of metastatic PPGL can only be established if metastases are found at "extra-chromaffin" sites. In the era of precision medicine with individually targeted therapies and advanced care of patients, the treatment options for metastatic pheochromocytoma/paraganglioma are still limited. With this review we would like to nurture the idea of the quest for non-coding ribonucleic acids as an area to be further investigated in tumor biology. Non-coding RNA molecules encompassing microRNAs, long non-coding RNAs, and circular RNAs have been implicated in the pathogenesis of various tumors, and were also proposed as valuable diagnostic, prognostic factors, and even potential treatment targets. Given the fact that the pathogenesis of tumors including pheochromocytomas/paragangliomas is linked to epigenetic dysregulation, it is reasonable to conduct studies related to their epigenetic expression profiles and in this brief review we present a synopsis of currently available findings on the relevance of these molecules in these tumors highlighting their diagnostic potential.

Citing Articles

Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer.

Fatima S, Kumar V, Kumar D Med Oncol. 2025; 42(3):61.

PMID: 39893601 DOI: 10.1007/s12032-025-02608-5.

Exploring the role of noncoding RNAs in cancer diagnosis, prognosis, and precision medicine.

Eldakhakhny B, Sutaih A, Siddiqui M, Aqeeli Y, Awan A, Alsayegh M Noncoding RNA Res. 2025; 9(4):1315-1323.

PMID: 39764154 PMC: 11703603. DOI: 10.1016/j.ncrna.2024.06.015.

Circulating non-coding RNA biomarkers of endocrine tumours.

Butz H, Patocs A, Igaz P Nat Rev Endocrinol. 2024; 20(10):600-614.

PMID: 38886617 DOI: 10.1038/s41574-024-01005-8.

Novel Insights into Circular RNAs in Metastasis in Breast Cancer: An Update.

Zepeda-Enriquez P, Silva-Cazares M, Lopez-Camarillo C Noncoding RNA. 2023; 9(5).

PMID: 37736901 PMC: 10514845. DOI: 10.3390/ncrna9050055.

Long noncoding RNA TFAP2A-AS1 exerts promotive effects in non-small cell lung cancer progression via controlling the microRNA-548a-3p/CDK4 axis as a competitive endogenous RNA.

Zhang Y, Ma L, Zhang T, Li P, Xu J, Wang Z Oncol Res. 2023; 29(2):129-139.

PMID: 37305398 PMC: 10208034. DOI: 10.32604/or.2022.03563.

References

Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves T, Pfeffer L . MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014; 16(4):R78. PMC: 4405876. DOI: 10.1186/bcr3693. View

Tian J, Xu H, Chen G, Wang H, Bi Y, Gao H . Roles of lncRNA UCA1-miR-18a-SOX6 axis in preventing hypoxia injury following cerebral ischemia. Int J Clin Exp Pathol. 2020; 10(8):8187-8198. PMC: 6965478. View

Chen X, Wu L, Li D, Xu Y, Zhang L, Niu K . Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both ATM and HIF-1α. Cancer Med. 2018; 7(8):3834-3847. PMC: 6089184. DOI: 10.1002/cam4.1527. View

Guo Z, Maki M, Ding R, Yang Y, Zhang B, Xiong L . Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues. Sci Rep. 2014; 4:5150. PMC: 5381490. DOI: 10.1038/srep05150. View

Guller U, Turek J, Eubanks S, DeLong E, Oertli D, Feldman J . Detecting pheochromocytoma: defining the most sensitive test. Ann Surg. 2005; 243(1):102-7. PMC: 1449983. DOI: 10.1097/01.sla.0000193833.51108.24. View

Ilanchezhian M, Jha A, Pacak K, Del Rivero J . Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options Oncol. 2020; 21(11):85. PMC: 7456409. DOI: 10.1007/s11864-020-00787-z. View

Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M . The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf). 2006; 65(3):287-93. DOI: 10.1111/j.1365-2265.2006.02591.x. View

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

Lenders J, Pacak K, Walther M, Linehan W, Mannelli M, Friberg P . Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002; 287(11):1427-34. DOI: 10.1001/jama.287.11.1427. View

10.

Ashwal-Fluss R, Meyer M, Pamudurti N, Ivanov A, Bartok O, Hanan M . circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56(1):55-66. DOI: 10.1016/j.molcel.2014.08.019. View

11.

Castro-Vega L, Letouze E, Burnichon N, Buffet A, Disderot P, Khalifa E . Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015; 6:6044. PMC: 4354166. DOI: 10.1038/ncomms7044. View

12.

Li Z, Huang C, Bao C, Chen L, Lin M, Wang X . Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015; 22(3):256-64. DOI: 10.1038/nsmb.2959. View

13.

Adameyko I, Lallemend F, Aquino J, Pereira J, Topilko P, Muller T . Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell. 2009; 139(2):366-79. DOI: 10.1016/j.cell.2009.07.049. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Enuka Y, Lauriola M, Feldman M, Sas-Chen A, Ulitsky I, Yarden Y . Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2015; 44(3):1370-83. PMC: 4756822. DOI: 10.1093/nar/gkv1367. View

16.

Drenou B, Le Tulzo Y, Caulet-Maugendre S, Le Guerrier A, Leclercq C, Guilhem I . Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv Rev Fr Hematol (1978). 1995; 37(3):197-9. View

17.

Alrezk R, Suarez A, Tena I, Pacak K . Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Front Endocrinol (Lausanne). 2018; 9:515. PMC: 6277481. DOI: 10.3389/fendo.2018.00515. View

18.

Lefebvre M, Foulkes W . Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol. 2014; 21(1):e8-e17. PMC: 3921052. DOI: 10.3747/co.21.1579. View

19.

Harrod T, Justement L . Evaluating function of transmembrane protein tyrosine phosphatase CD148 in lymphocyte biology. Immunol Res. 2002; 26(1-3):153-66. DOI: 10.1385/ir:26:1-3:153. View

20.

Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D . Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009; 24(4):652-7. DOI: 10.1111/j.1440-1746.2008.05666.x. View